Targeting the High-Density Lipoprotein Proteome for the Treatment of Post-Acute Sequelae of SARS-CoV-2
Here, we target the high-density lipoprotein (HDL) proteome in a case series of 16 patients with post-COVID-19 symptoms treated with HMG-Co-A reductase inhibitors (statin) plus angiotensin II type 1 receptor blockers (ARBs) for 6 weeks. Patients suffering from persistent symptoms (postacute seque...
Saved in:
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Philipps-Universität Marburg
2024
|
Subjects: | |
Online Access: | PDF Full Text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Here, we target the high-density lipoprotein (HDL) proteome in a case series of 16 patients
with post-COVID-19 symptoms treated with HMG-Co-A reductase inhibitors (statin) plus angiotensin
II type 1 receptor blockers (ARBs) for 6 weeks. Patients suffering from persistent symptoms (postacute
sequelae) after serologically confirmed SARS-CoV-2 infection (post-COVID-19 syndrome, PCS,
n = 8) or following SARS-CoV-2 vaccination (PVS, n = 8) were included. Asymptomatic subjects with
corresponding serological findings served as healthy controls (n = 8/8). HDL was isolated using
dextran sulfate precipitation and the HDL proteome of all study participants was analyzed quantitatively
by mass spectrometry. Clinical symptoms were assessed using questionnaires before and
after therapy. The inflammatory potential of the patients’ HDL proteome was addressed in human
endothelial cells. The HDL proteome of patients with PCS and PVS showed no significant differences;
however, compared to controls, the HDL from PVS/PCS patients displayed significant alterations
involving hemoglobin, cytoskeletal proteins (MYL6, TLN1, PARVB, TPM4, FLNA), and amyloid
precursor protein. Gene Ontology Biological Process (GOBP) enrichment analysis identified hemostasis,
peptidase, and lipoprotein regulation pathways to be involved. Treatment of PVS/PCS patients
with statins plus ARBs improved the patients’ clinical symptoms. After therapy, three proteins were
significantly increased (FAM3C, AT6AP2, ADAM10; FDR < 0.05) in the HDL proteome from patients
with PVS/PCS. Exposure of human endothelial cells with the HDL proteome from treated PVS/PCS
patients revealed reduced inflammatory cytokine and adhesion molecule expression. Thus, HDL
proteome analysis from PVS/PCS patients enables a deeper insight into the underlying disease
mechanisms, pointing to significant involvement in metabolic and signaling disturbances. Treatment
with statins plus ARBs improved clinical symptoms and reduced the inflammatory potential of the
HDL proteome. These observations may guide future therapeutic strategies for PVS/PCS patients. |
---|---|
Item Description: | Gefördert durch den Open-Access-Publikationsfonds der UB Marburg. |
Physical Description: | 19 Pages |
DOI: | 10.3390/ijms25084522 |